axa1125
Long COVID-19
Axcella Health, IncPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
31 Active assets in the Long COVID-19 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Immulina Tm University of Mississippi Medical Center | Phase 3 | BB |
MELATONIN Duke University | Phase 2 | B |
Rapamycin Icahn School of Medicine at Mount Sinai | Phase 3 | B |
Paxlovid Kanecia Obie Zimmerman | Phase 2 | B |
RITONAVIR Kanecia Obie Zimmerman | Phase 2 | B |
View all 31 →
Same molecule, other indications
axa1125 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →